Merck Patent Gmbh

Pfizer Corporation

Markus Weigandt

Andrea Hanefeld

Armin Kuebelbeck

Gregor Larbig

Stefan Schiller

Simon Geissler

Senta Voss

Michael Wolf

Alessandra Del Rio

Gianluca Rinaldi

Silvia Fratarcangeli

Hartwig Steckel

Michael Lange

Matthias Schroeder

Carsten Schmidt

Peter Walden

Achim Goepferich

Markus Klemm

Marc Schneider

Holger Kubas

Regina Scherliess

Martina Jeschke

Patrizia Boniforte

Meike Harms

Andrea Diedrich

Renato Brito Baleeiro

Percy Knolle

Tobias Miller

Michael C Lehr

Silvia Fratar-Cangeli

Markus Riehl

Gero Hooff

Corinna Schoch

Claus Michael Lehr

A pharmaceutical formulation has (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol or pharmaceutically acceptable salt thereof.

Pharmaceutical formulation

The present invention relates to a solid pharmaceutical preparation of 3-Fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1H-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl]-benzonitrile, a method of making same, and medical uses thereof.

Pharmaceutical preparation

The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.

Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab

The present invention is directed to a process for the preparation of enteric microparticles comprising nanoparticles, wherein the nanoparticles comprise a matrix and an active ingredient. The microparticles obtained by such process are usable various multiparticulate pharmaceutical formulations such as extemporaneous dosage forms (powder for reconstitution).

Preparation of nanoparticles-releasing enteric microparticles

The present invention relates to a novel process for the production of nanoparticles laden with active compounds and to the use thereof as medicaments. The process for the production of nanoparticles comprises the steps (a) dissolution of at least one active compound and at least one polymer in an organic solvent, (b) mixing of the solution prepared in step (a) with an aqueous phase, (c) evaporation of the organic solvent, (d) purification of the nanoparticles laden with active compound obtained in step (c) by means of dialysis against aqueous dialysis solution comprising the same active compound.

Process for producing nanoparticles laden with active ingredient

The present invention is directed to nanoparticles comprising chitosan and an antigen, whereby the chitosan has a degree of deacetylation of about 90% and a molecular weight from 5 kDa to 80 kDa, to microparticles containing such nanoparticles as well as to a process for preparation of such particles. The particles are usable for vaccination.

Antigen-loaded chitosan nanoparticles for immunotherapy

The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunisation of a mammal.

Silicon dioxide nanoparticles and the use thereof for vaccination

The invention relates to ultrasmall, monodisperse nanoparticles comprising silicon dioxide to the surface of which at least one antigen is attached. The nanoparticles can be used for the immunoprophylaxis or immunotherapy of cancer. The invention also relates to a method for the targeting of antigens at antigen-presenting cells and for the activation of the immune system, where the efficiency of targeting and/or immunoactivation are set via the particle characteristics. The invention also relates to a method for the active and passive immunization of a mammal.

Growing community of inventors

Mannheim, Germany

Markus Weigandt